Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Betamethason und Salicylsäure (ausschl. Dafo. LOE), f. d. Z. 01.07.26 - 30.06.28 (zzgl. V.-Option 1x12 Mon)

Section 130a, paragraph 8, of the German Social Code (SGB V) allows health insurance funds and pharmaceutical companies to conclude framework discount agreements for medicines to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal provisions for the award of public contracts, the DAK-Gesundheit regularly conducts substance-related, formal tendering procedures in accordance with the regulations of Part 4 of the German Competition Act (GWB). For medicines to be specified by the bidder in more detail in Annex 2 to the contract, for the aforementioned active substance Betamethasone and Salicylic Acid (exclusively in the form of LOE), ATC D07XC01, the DAK-Gesundheit intends to conclude medicine discount agreements with as many interested pharmaceutical companies as possible until the entry into force of new medicine discount agreements. A discount agreement under the authorisation model for the aforementioned active substance comes into force for the first time on 01.07.2026 and ends on 30.06.2028 (plus extension option 1x12 months). It ends automatically with the entry into force of the exclusive agreement, regardless.